Navigation Links
Nephros Announces Split Adjusted Trade Date
Date:3/15/2011

The patented dual stage cold sterilization ultrafilter has the capability to filter out bacteria and, due to its exceptional filtration levels, filter out many viruses, parasites and biotoxins. Nephros's DSUs are being evaluated at several major U.S. medical centers for infection control. The DSU has also been selected for further development by the U.S. Marine Corps for purification of drinking water by soldiers in the field.

For more information about Nephros, please visit the company's website at www.nephros.com.

Forward-Looking Statements

Statements in this news release that are not historical facts constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Such statements may be preceded by words such as "may," "plans," "expects," "believes," "hopes," "potential" or similar words. For such statements, Nephros claims the protection of the PSLRA.

Forward-looking statements are not guarantees of future performance, are based on assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond Nephros' control. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that Nephros may not be able: (i) to complete the rights offering and private placement; (ii) to continue as a going concern; (iii) to obtain additional funding when needed or on favorable terms; (iv) to obtain appropriate or necessary governmental approvals to achieve its business plan or effectively market its products; (v) to have its technologies and products accepted in current or future target markets; (vi) to demonstrate in pre-clinical or clinical trials the anticipated efficacy, safety or cost savings of products that appeared promising to Nephros in research or clini
'/>"/>

SOURCE Nephros, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
2. Nephros Reports 2009 Third Quarter Financial Results
3. Nephros Signs Canadian Distribution Agreement with Bellco Health Care Inc.
4. Nephros Signs Development Agreement with STERIS
5. Nephros Reports 2010 First Quarter Financial Results
6. Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems
7. Nephros Receives Formal Response from FDA for 510(k) Application for Hemodiafiltration System
8. Nephros Reports 2010 Second Quarter Financial Results
9. Nephros Completes Bridge Financing and Announces Stockholder Rights Offering
10. Nephros Reports 2010 Third Quarter Financial Results
11. Nephros Rights Offering Registration Statement Declared Effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014 The Female Health ... an investor conference call to discuss its operating results ... 30, 2014 on Tuesday, December 2, 2014 at 11:00 ... report its operating results earlier the same day. ... the conference call by dialing 1-877-374-8416 (international participants dial ...
(Date:11/24/2014)... Nov. 24, 2014  GlySens Incorporated announced today that ... grant from the National Institute of Diabetes and Digestive ... Institutes of Health (NIH).  The grant is intended to ... ICGM™ long term implantable glucose monitoring system.  Final preparations ... is expected to begin before the end of 2014. ...
(Date:11/24/2014)... DEVON, England , Nov. 24, 2014 /PRNewswire/ ... https://www.facebook.com/PifflersUnited announced the release of results ... pain therapy device, in the self-management of fibromyalgia ... the area of worst pain, very significant clinically ... The 140 group members with fibromyalgia used ...
Breaking Medicine Technology:The Female Health Company To Report FY2014 Operating Results on Tuesday, December 2, 2014 2GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 2Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 3
... today that eleven presentations or publications on pre-clinical and ... several major tumor types will be made during the ... May 29-June 2, in Orlando, Florida. Abstracts are ... http://www.newscom.com/cgi-bin/prnh/20090227/PH75873LOGO ) Prostate Cancer ...
... (LSE: SHP, Nasdaq: SHPGY ), the global specialty ... of the ADHD medication VYVANSE(R) (lisdexamfetamine dimesylate) CII with the ... X 2), did not alter the median time it took ... reached in the subjects evaluated. In the same study, ...
Cached Medicine Technology:Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting 2Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting 3New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 2New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 3New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 4New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 5New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 6New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 7New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 8
(Date:11/23/2014)... 2014 The clinical trial report, ... data on the Aspergillosis clinical trial scenario. This ... the clinical trials on Aspergillosis. It includes an ... status as per the site of trial conduction ... coverage of disease clinical trials by their phase, ...
(Date:11/23/2014)... Tbdress.com has recently announced that its Special ... 2014. The special offer will provide ladies many gorgeous shoes ... the world’s largest women’s dresses retailers, and its shoes include ... great discounts on that day: Everything at Tbdress.com is up ... above $89). , People can use the following coupon codes ...
(Date:11/23/2014)... SUNDAY, Nov. 23, 2014 (HealthDay News) -- The holidays ... autism because sensory overload can trigger major meltdowns, an ... under the best of circumstances, but when you have ... Varleisha Gibbs, an occupational therapy professor at University of ... release. "It,s best to let your hosts or ...
(Date:11/23/2014)... SWAccessControl.com's high quality access control power suppliers ... has announced its new collection of power suppliers. Additionally, ... quality power suppliers. All the new models come with ... lasts until Dec. 20, 2014. , SWAccessControl.com has thousands ... supporting it for a long time. It is very ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 “BlackVue” was ... Tech Report , which features the latest and coolest ... expert and reporter for NewsWatch, conducted the product review ... unique and powerful options in the car camera industry. ... and it can be hard to find the one ...
Breaking Medicine News(10 mins):Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Tbdress.com Special Friday Shoes Sales Online Now 2Health News:Holidays Can Be Sensory Overload for Kids With Autism 2Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:A Leader in Front and Rear Facing In-Car Cameras was Featured on NewsWatch Television on October 30, 2014 2
... ... ... ... ...
... ... ... ... ...
... ... ... , ... TULSA, Okla. , Feb. 19 U.S. ...
... more fumes that are likely carcinogenic than with electric ranges ... hot stove -- make that a hot gas ... cancer. , Researchers in Norway have found that cooking with ... , But, in a report published online Feb. 17 in ...
... (P4P) programs are payment models that reward workers for ... the healthcare setting, P4P programs use a variety of ... fee differentials and bonuses. A new study ... that P4P programs appear to be effective in incentivizing ...
... ... momentum created by local communities and the NGO Tostan to end the practice by 2015 ... Dakar, Senegal (PRWEB) February ... cutting (FGC) which has seen thousands of communities in Senegal join its ranks in recent ...
Cached Medicine News:Health News:New Gallup Poll Quantifies U.S. Physician Opinions on the Scope of Defensive Medicine Practices 2Health News:New Gallup Poll Quantifies U.S. Physician Opinions on the Scope of Defensive Medicine Practices 3Health News:New Gallup Poll Quantifies U.S. Physician Opinions on the Scope of Defensive Medicine Practices 4Health News:Abbott Announces 10 Percent Increase in Quarterly Dividend 2Health News:Abbott Announces 10 Percent Increase in Quarterly Dividend 3Health News:Two Tulsa Pharmacies Penalized for Missing Prescription Drugs 2Health News:Two Tulsa Pharmacies Penalized for Missing Prescription Drugs 3Health News:Gas Cooking Might Up Your Cancer Risk 2Health News:Gas Cooking Might Up Your Cancer Risk 3Health News:Senegal: Total End of Female Genital Cutting Now in Sight 2
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Escherichia coli - For the qualitative detection of Escherichia coli 0157 and 0157:H7 in food products Accessories BinaxNOW EH E.coli 0157 & 0157:H7 Control Swab Pack (510-000) ...
Medicine Products: